View Document Preview and Link Document Date: 2014-05-20 20:50:31 Open Document File Size: 652,85 KB Share Result on Facebook
Company Pharmacybrands Ltd / Merck / / Continent Europe / / Country Netherlands / New Zealand / United States / Canada / Australia / United Kingdom / / Event FDA Phase / / Facility The American College of Physicians / / IndustryTerm state law / healthcare consumers / immunisation applications / handbook printing / prevention of herpes / / MedicalCondition medicine Zoster / Ingredients Varicella / chickenpox / herpes zoster / Shingles / strain / dysfunction / skin rash / anaphylaxis / zoster infection / vaccine Shingles / acute and chronic zoster / epidemics / Reclassify Zoster / illness / dormant varicella zoster virus / influenza / Zoster / earlier chickenpox infection / insomnia / congestive heart failure / post-herpetic neuralgia / elderly shingles / Stroke / vaccine Chickenpox / ganglion / itching / varicella zoster / rash onset / pain / diabetes mellitus / varicella zoster virus / encephalitis / chronic medical conditions / infection / postherpetic neuralgia / depression / meningitis / Varicella / / MedicalTreatment immunization / vaccination / surgery / vaccinations / / Movie Quality of life / / NaturalFeature Oka / / Organization American Society of Internal Medicine / Centre for Adverse Reactions Monitoring / Immunisation Advisory Centre / The American College / Ministry of Health Immunisation Handbook / Ministry of Health / / Position Pharmacist / physician / licensed pharmacist / / Product Zoster vaccine / / SocialTag 
Submission for Reclassification of the Zoster Vaccine for use in Adults Executive Summary This application requests a reclassification for the Zoster vaccination allowing administration to people aged 50 years or over by